Flagship Harbor Advisors LLC bought a new position in shares of Nektar Therapeutics (NASDAQ:NKTR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,913 shares of the biopharmaceutical company’s stock, valued at approximately $142,000.

Other institutional investors have also modified their holdings of the company. World Asset Management Inc raised its holdings in shares of Nektar Therapeutics by 16.6% during the second quarter. World Asset Management Inc now owns 10,646 shares of the biopharmaceutical company’s stock worth $520,000 after purchasing an additional 1,513 shares during the last quarter. MetLife Investment Advisors LLC raised its holdings in shares of Nektar Therapeutics by 72.3% during the first quarter. MetLife Investment Advisors LLC now owns 115,385 shares of the biopharmaceutical company’s stock worth $12,261,000 after purchasing an additional 48,428 shares during the last quarter. Gateway Investment Advisers LLC purchased a new position in shares of Nektar Therapeutics during the second quarter worth $342,000. LMR Partners LLP purchased a new position in shares of Nektar Therapeutics during the second quarter worth $6,378,000. Finally, Alpine Global Management LLC purchased a new position in shares of Nektar Therapeutics during the first quarter worth $1,901,000. 92.22% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently issued reports on NKTR shares. BidaskClub raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, June 19th. William Blair reissued a “buy” rating on shares of Nektar Therapeutics in a report on Monday, June 4th. HC Wainwright reduced their target price on shares of Nektar Therapeutics to $97.00 and set a “buy” rating for the company in a report on Monday, June 4th. Piper Jaffray Companies set a $125.00 target price on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Wednesday, July 25th. Finally, Zacks Investment Research raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 target price for the company in a report on Monday, July 16th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $82.91.

NKTR stock opened at $59.25 on Friday. The firm has a market cap of $10.84 billion, a P/E ratio of -107.73 and a beta of 2.27. The company has a current ratio of 19.67, a quick ratio of 19.55 and a debt-to-equity ratio of 0.13. Nektar Therapeutics has a one year low of $21.11 and a one year high of $111.36.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported $5.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $5.22 by $0.11. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.03 billion. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. The firm’s revenue was up 3043.7% on a year-over-year basis. During the same quarter last year, the business earned ($0.39) earnings per share. research analysts predict that Nektar Therapeutics will post 3.77 earnings per share for the current year.

In other Nektar Therapeutics news, CEO Howard W. Robin sold 130,000 shares of the company’s stock in a transaction on Wednesday, June 27th. The shares were sold at an average price of $49.52, for a total transaction of $6,437,600.00. Following the completion of the transaction, the chief executive officer now owns 267,690 shares in the company, valued at approximately $13,256,008.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director R Scott Greer sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $67.39, for a total transaction of $673,900.00. Following the transaction, the director now owns 140,333 shares of the company’s stock, valued at approximately $9,457,040.87. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 262,584 shares of company stock worth $14,125,718. 4.31% of the stock is owned by company insiders.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

See Also: Determine Your Level of Risk Tolerance

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.